Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection

Author(s): Majid T. Moghadam, Zahra Chegini, Amin Norouzi, Amin S. Dousari and Aref Shariati*

Volume 22, Issue 7, 2021

Published on: 07 August, 2020

Page: [945 - 959] Pages: 15

DOI: 10.2174/1389201021666200807110849

Price: $65

Abstract

Background: Helicobacter pylori causes dangerous and deadly diseases such as gastric cancer and duodenal ulcers. Eradication and treatment of this bacterium are very important due to the deadly diseases caused by H. pylori and the high cost of treatment for countries.

Methods: Thus, we present a complete list of the most important causes of failure in the treatment and eradication of H. pylori, and address new therapeutic methods that may be effective in controlling this bacterium in the future.

Results: Many efforts have been made to control and eradicate this bacterium over the years, but no success has been achieved since its eradication is a complex process affected by the bacterial properties and host factors. Previous studies have shown that various factors are involved in the failure to eradicate H. pylori, such as new genotypes of the bacterium with higher pathogenicity, inappropriate patient cooperation, mutations, biofilm formation and dormant forms that cause antibiotic resistance, acidic stomach pH, high bacterial load, smoking, immunosuppressive features and intracellular occurrence of H. pylori. On the other hand, recent studies reported that the use of probiotics, nanoparticles, antimicrobial peptides, natural product and vaccines can be helpful in the treatment and eradication of H. pylori infections.

Conclusion: Eradication of H. pylori is crucial for the treatment of important diseases such as gastric cancer. Therefore, it seems that identifying the failure causes of treating this bacterium can be helpful in controlling the infections. Besides, further studies on new therapeutic strategies may help eradicate H. pylori in the future.

Keywords: Helicobacter pylori, eradication failure, gastric cancer, peptic ulcers, new therapeutic strategies, refractory Helicobacter pylori infection.

« Previous Next »
Graphical Abstract

[1]
Blaser, M.J. Helicobacter pylori and esophageal disease: Wake-up call? Gastroenterology, 2010, 139(6), 1819-1822.
[http://dx.doi.org/10.1053/j.gastro.2010.10.037] [PMID: 21029801]
[2]
Penston, J.G. Review article: Helicobacter pylori eradication-understandable caution but no excuse for inertia. Aliment. Pharmacol. Ther., 1994, 8(4), 369-389.
[http://dx.doi.org/10.1111/j.1365-2036.1994.tb00304.x] [PMID: 7986962]
[3]
Hunt, R.H.; Xiao, S.D.; Megraud, F.; Leon-Barua, R.; Bazzoli, F.; van der Merwe, S.; Vaz Coelho, L.G.; Fock, M.; Fedail, S.; Cohen, H.; Malfertheiner, P.; Vakil, N.; Hamid, S.; Goh, K.L.; Wong, B.C.; Krabshuis, J.; Le Mair, A. World Gastroenterology Organization; World Gastroenterology Organisation Global Guideline. Helicobacter pylori in developing countries. J. Gastrointestin. Liver Dis., 2011, 20(3), 299-304.
[PMID: 21961099]
[4]
Ohata, H.; Kitauchi, S.; Yoshimura, N.; Mugitani, K.; Iwane, M.; Nakamura, H.; Yoshikawa, A.; Yanaoka, K.; Arii, K.; Tamai, H.; Shimizu, Y.; Takeshita, T.; Mohara, O.; Ichinose, M. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer, 2004, 109(1), 138-143.
[http://dx.doi.org/10.1002/ijc.11680] [PMID: 14735480]
[5]
Azimi, T.; Nasser, A.; Shariati, A.; Shiadeh, S.M.J.; Safari, H.; Alizade-Sani, M.; Taghipour, A.; Dehghan, A. The possible role of pathogenic and non-pathogenic bacteria in initiation and exacerbation of celiac disease; A comprehensive review. Curr. Pharm. Biotechnol., 2020, 21(6), 452-466.
[http://dx.doi.org/10.2174/1389201021666191219160729] [PMID: 31858910]
[6]
Darbandi, A.; Mirshekar, M.; Shariati, A.; Moghadam, M.T.; Lohrasbi, V.; Asadolahi, P.; Talebi, M. The effects of probiotics on reducing the colorectal cancer surgery complications: A periodic review during 2007-2017. Clin. Nutr., 2019, S0261-5614(19), 33135-33138.
[http://dx.doi.org/10.1016/j.clnu.2019.11.008] [PMID: 31831184]
[7]
Eidt, S.; Stolte, M.; Fischer, R. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas. J. Clin. Pathol., 1994, 47(5), 436-439.
[http://dx.doi.org/10.1136/jcp.47.5.436] [PMID: 8027397]
[8]
Zumkeller, N.; Brenner, H.; Zwahlen, M.; Rothenbacher, D. Helicobacter pylori infection and colorectal cancer risk: A meta-analysis. Helicobacter, 2006, 11(2), 75-80.
[http://dx.doi.org/10.1111/j.1523-5378.2006.00381.x] [PMID: 16579836]
[9]
Bugaytsova, J.; Chernov, Y.A.; Gideonsson, P.; Mendez, M.; Henriksson, S.; Mahdavi, J.; Quintana-Hayashi, M.; Shevtsova, A.; Sjöström, R.; Moskalenko, R. Acid responsive Helicobacter pylori adherence: Implications for chronic infection and disease. Cell Host Microbe, 2016, 21(3), 318-320.
[10]
Rothenbacher, D.; Brenner, H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: Recent developments and future implications. Microbes Infect., 2003, 5(8), 693-703.
[http://dx.doi.org/10.1016/S1286-4579(03)00111-4] [PMID: 12814770]
[11]
Smith, S.I.; Seriki, A.; Ndip, R.; Pellicano, R. Helicobacter pylori infection in Africa: 2018 literature update. Minerva Gastroenterol. Dietol., 2018, 64(3), 222-234.
[http://dx.doi.org/10.23736/S1121-421X.18.02464-9] [PMID: 29327819]
[12]
Amaral, O.; Fernandes, I.; Veiga, N.; Pereira, C.; Chaves, C.; Nelas, P.; Silva, D. Living conditions and Helicobacter pylori in adults. BioMed Res. Int., 2017., , Article ID 9082716..
[http://dx.doi.org/10.1155/2017/9082716]
[13]
Muhammad, J.S.; Zaidi, S.F.; Sugiyama, T. Epidemiological ins and outs of Helicobacter pylori: A review. J. Pak. Med. Assoc., 2012, 62(9), 955-959.
[PMID: 23139983]
[14]
Dube, C.; Nkosi, T.C.; Clarke, A.M.; Mkwetshana, N.; Green, E.; Ndip, R.N. Helicobacter pylori antigenemia in an asymptomatic population of Eastern Cape Province, South Africa: Public health implications. Rev. Environ. Health, 2009, 24(3), 249-255.
[http://dx.doi.org/10.1515/REVEH.2009.24.3.249] [PMID: 19891122]
[15]
Iwamoto, A.; Tanahashi, T.; Okada, R.; Yoshida, Y.; Kikuchi, K.; Keida, Y.; Murakami, Y.; Yang, L.; Yamamoto, K.; Nishiumi, S.; Yoshida, M.; Azuma, T. Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes. Gut Pathog., 2014, 6(1), 27.
[http://dx.doi.org/10.1186/1757-4749-6-27] [PMID: 24995043]
[16]
Rauws, E. Therapeitic attempts at eradication of Campylobacter pylori. Eur. J. Gastroenterol. Hepatol., 1989, 1, 34.
[17]
Marshall, B.J.; Armstrong, J.A.; Francis, G.J.; Nokes, N.T.; Wee, S.H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion, 1987, 37(Suppl. 2), 16-30.
[http://dx.doi.org/10.1159/000199555] [PMID: 3622946]
[18]
Glupczynski, Y.; Burette, A. Drug therapy for Helicobacter pylori infection: Problems and pitfalls. Am. J. Gastroenterol., 1990, 85(12), 1545-1551.
[PMID: 2174642]
[19]
Rauws, E.A.; van der Hulst, R.W. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs, 1995, 50(6), 984-990.
[http://dx.doi.org/10.2165/00003495-199550060-00006] [PMID: 8612476]
[20]
Unge, P.; Gad, A.; Gnarpe, H.; Olsson, J. Does omeprazole improve antimicrobial therapy directed towards gastric campylobacter pylori in patients with antral gastritis?: A pilot study. Scand. J. Gastroenterol., 1989, 24(167), 49-54.
[21]
Van der Hulst, R.; Tytgat, G. Helicobacter pylori and peptic ulcer disease. Scand. J. Gastroenterol., 1996, 31, 10-18.
[22]
Marshall, B. Helicobacter pylori: 20 Years on. Clin. Med. (Lond.), 2002, 2(2), 147-152.
[http://dx.doi.org/10.7861/clinmedicine.2-2-147] [PMID: 11991099]
[23]
Bazzoli, F. My approach to Helicobacter pylori eradication. Eur. J. Gastroenterol. Hepatol., 1999, 11(Suppl. 1), S37-S41.
[http://dx.doi.org/10.1097/00042737-199906001-00007] [PMID: 10443911]
[24]
Glupczynski, Y.; Burette, A.; De Koster, E.; Nyst, J-F.; Deltenre, M.; Cadranel, S.; Bourdeaux, L.; De Vos, D. Metronidazole resistance in Helicobacter pylori. Lancet, 1990, 335(8695), 976-977.
[http://dx.doi.org/10.1016/0140-6736(90)91043-A] [PMID: 1970050]
[25]
Rinaldi, V.; Zullo, A.; Pugliano, F.; Valente, C.; Diana, F.; Attili, A.F. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 1997, 11(5), 929-933.
[http://dx.doi.org/10.1046/j.1365-2036.1997.00228.x] [PMID: 9354202]
[26]
Delport, W.; Cunningham, M.; Olivier, B.; Preisig, O.; van der Merwe, S.W. A population genetics pedigree perspective on the transmission of Helicobacter pylori. Genetics, 2006, 174(4), 2107-2118.
[http://dx.doi.org/10.1534/genetics.106.057703] [PMID: 17057244]
[27]
Yonezawa, H.; Osaki, T.; Hojo, F.; Kamiya, S. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin. Microb. Pathog., 2019, 132, 100-108.
[http://dx.doi.org/10.1016/j.micpath.2019.04.030] [PMID: 31034965]
[28]
Mégraud, F. Transmission of Helicobacter pylori: Faecal-oral versus oral-oral route. Aliment. Pharmacol. Ther., 1995, 9(Suppl. 2), 85-91.
[PMID: 8547533]
[29]
Lehours, P.; Yilmaz, O. Epidemiology of Helicobacter pylori infection. Helicobacter, 2007, 12(Suppl. 1), 1-3.
[http://dx.doi.org/10.1111/j.1523-5378.2007.00541.x] [PMID: 17727452]
[30]
Atapoor, S.; Safarpoor Dehkordi, F.; Rahimi, E. Detection of Helicobacter pylori in various types of vegetables and salads. Jundishapur J. Microbiol., 2014, 7(5), e10013.
[http://dx.doi.org/10.5812/jjm.10013] [PMID: 25147709]
[31]
Gomes, B.; De Martinis, E. The significance of Helicobacter pylori in water, food and environmental samples. Food Control, 2004, 15(5), 397-403.
[http://dx.doi.org/10.1016/S0956-7135(03)00106-3]
[32]
Sjomina, O.; Pavlova, J.; Niv, Y.; Leja, M. Epidemiology of Helicobacter pylori infection. Helicobacter, 2018, 23((Suppl. 1),), e12514.
[http://dx.doi.org/10.1111/hel.12514] [PMID: 30203587]
[33]
Parray, S.; Malik, S.; Basu, J.; Rashid, S.; Malik, G. Helicobacter pylori prevalence in Professional workers in main teaching Hospitals of Kashmir Valley. J.K. Pract., 2006, 13(2), 95-97.
[34]
Eslick, G.D. Helicobacter pylori infection transmitted sexually via oral-genital contact: A hypothetical model. Sex. Transm. Infect., 2000, 76(6), 489-492.
[http://dx.doi.org/10.1136/sti.76.6.489] [PMID: 11221134]
[35]
Okoli, A.S.; Menard, A.; Mendz, G.L. Helicobacter spp. other than Helicobacter pylori. Helicobacter, 2009, 14(Suppl. 1), 69-74.
[http://dx.doi.org/10.1111/j.1523-5378.2009.00701.x] [PMID: 19712171]
[36]
Flores-Treviño, C.E.; Urrutia-Baca, V.H.; Gómez-Flores, R.; De La Garza-Ramos, M.A.; Sánchez-Chaparro, M.M.; Garza-Elizondo, M.A. Molecular detection of Helicobacter pylori based on the presence of cagA and vacA virulence genes in dental plaque from patients with periodontitis. J. Dent. Sci., 2019, 14(2), 163-170.
[http://dx.doi.org/10.1016/j.jds.2019.01.010] [PMID: 31210890]
[37]
Dowsett, S.A.; Archila, L.; Segreto, V.A.; Gonzalez, C.R.; Silva, A.; Vastola, K.A.; Bartizek, R.D.; Kowolik, M.J. Helicobacter pylori infection in indigenous families of Central America: Serostatus and oral and fingernail carriage. J. Clin. Microbiol., 1999, 37(8), 2456-2460.
[http://dx.doi.org/10.1128/JCM.37.8.2456-2460.1999] [PMID: 10405384]
[38]
Wang, J.; Chen, R-C.; Zheng, Y-X.; Zhao, S-S.; Li, N.; Zhou, R-R.; Huang, Y.; Huang, Z-B.; Fan, X-G. Helicobacter pylori infection may increase the risk of progression of chronic hepatitis B disease among the Chinese population: A meta-analysis. Int. J. Infect. Dis., 2016, 50, 30-37.
[http://dx.doi.org/10.1016/j.ijid.2016.07.014] [PMID: 27457918]
[39]
Franceschi, F.; Tortora, A.; Gasbarrini, G.; Gasbarrini, A. Helicobacter pylori and extragastric diseases. Helicobacter, 2014, 19(Suppl. 1), 52-58.
[http://dx.doi.org/10.1111/hel.12159] [PMID: 25167946]
[40]
Gravina, A.G.; Zagari, R.M.; De Musis, C.; Romano, L.; Loguercio, C.; Romano, M. Helicobacter pylori and extragastric diseases: A review. World J. Gastroenterol., 2018, 24(29), 3204-3221.
[http://dx.doi.org/10.3748/wjg.v24.i29.3204] [PMID: 30090002]
[41]
Park, J.Y.; Dunbar, K.B.; Mitui, M.; Arnold, C.A.; Lam-Himlin, D.M.; Valasek, M.A.; Thung, I.; Okwara, C.; Coss, E.; Cryer, B.; Doern, C.D. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig. Dis. Sci., 2016, 61(8), 2373-2380.
[http://dx.doi.org/10.1007/s10620-016-4091-8] [PMID: 26923948]
[42]
Suzuki, H.; Mori, H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J. Gastroenterol., 2018, 53(3), 354-361.
[http://dx.doi.org/10.1007/s00535-017-1407-1] [PMID: 29138921]
[43]
Heep, M.; Kist, M.; Strobel, S.; Beck, D.; Lehn, N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur. J. Clin. Microbiol. Infect. Dis., 2000, 19(7), 538-541.
[http://dx.doi.org/10.1007/s100960000288] [PMID: 10968325]
[44]
Alouf, J.E.; Ladant, D.; Popoff, M.R. The comprehensive sourcebook of bacterial protein toxins; Elsevier, 2005.
[45]
Shibata, W.; Hirata, Y.; Yoshida, H.; Otsuka, M.; Hoshida, Y.; Ogura, K.; Maeda, S.; Ohmae, T.; Yanai, A.; Mitsuno, Y.; Seki, N.; Kawabe, T.; Omata, M. NF-kappaB and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection. World J. Gastroenterol., 2005, 11(39), 6134-6143.
[http://dx.doi.org/10.3748/wjg.v11.i39.6134] [PMID: 16273640]
[46]
El Khadir, M.; Alaoui Boukhris, S.; Benajah, D-A.; El Rhazi, K.; Ibrahimi, S.A.; El Abkari, M.; Harmouch, T.; Nejjari, C.; Mahmoud, M.; Benlemlih, M.; Bennani, B. VacA and cagA status as biomarker of two opposite end outcomes of Helicobacter pylori infection (gastric cancer and duodenal ulcer) in a Moroccan population. PLoS One, 2017, 12(1), e0170616.
[http://dx.doi.org/10.1371/journal.pone.0170616] [PMID: 28125638]
[47]
van Doorn, L-J.; Schneeberger, P.M.; Nouhan, N.; Plaisier, A.P.; Quint, W.G.; de Boer, W.A. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut, 2000, 46(3), 321-326.
[http://dx.doi.org/10.1136/gut.46.3.321] [PMID: 10673291]
[48]
Zhang, M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J. Gastroenterol., 2015, 21(48), 13432-13437.
[http://dx.doi.org/10.3748/wjg.v21.i48.13432] [PMID: 26730153]
[49]
Boyanova, L.; Evstatiev, I.; Yordanov, D.; Markovska, R.; Mitov, I. Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance. Folia Microbiol. (Praha), 2016, 61(4), 307-310.
[http://dx.doi.org/10.1007/s12223-015-0439-2] [PMID: 26634607]
[50]
Molina-Infante, J.; Romano, M.; Fernandez-Bermejo, M.; Federico, A.; Gravina, A.G.; Pozzati, L.; Garcia-Abadia, E.; Vinagre-Rodriguez, G.; Martinez-Alcala, C.; Hernandez-Alonso, M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology, 2013, 145(1), 121-128.
[http://dx.doi.org/10.1053/j.gastro.2013.03.050]
[51]
Zhang, M-M.; Qian, W.; Qin, Y-Y.; He, J.; Zhou, Y-H. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J. Gastroenterol., 2015, 21(14), 4345-4357.
[http://dx.doi.org/10.3748/wjg.v21.i14.4345] [PMID: 25892886]
[52]
Farup, P.G.; Tholfsen, J.; Wetternus, S.; Torp, R.; Høie, O.; Lange, O.J. Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand. J. Gastroenterol., 2002, 37(12), 1374-1379.
[http://dx.doi.org/10.1080/003655202762671233] [PMID: 12523585]
[53]
Chew, C.A.Z.; Lye, T.F.; Ang, D.; Ang, T.L. The diagnosis and management of H. pylori infection in Singapore. Singapore Med. J., 2017, 58(5), 234-240.
[http://dx.doi.org/10.11622/smedj.2017037] [PMID: 28536725]
[54]
Mégraud, F.; Lamouliatte, H. Review article: The treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther., 2003, 17(11), 1333-1343.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01592.x] [PMID: 12786627]
[55]
Li, H.; Liang, X.; Chen, Q.; Zhang, W.; Lu, H. Inappropriate treatment in Helicobacter pylori eradication failure: A retrospective study. Scand. J. Gastroenterol., 2018, 53(2), 130-133.
[http://dx.doi.org/10.1080/00365521.2017.1413132] [PMID: 29214879]
[56]
Romano, M.; Iovene, M.R.; Russo, M.I.; Rocco, A.; Salerno, R.; Cozzolino, D.; Pilloni, A.P.; Tufano, M.A.; Vaira, D.; Nardone, G. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J. Clin. Pathol., 2008, 61(10), 1112-1115.
[http://dx.doi.org/10.1136/jcp.2008.060392] [PMID: 18755715]
[57]
Sanches, B.S.; Martins, G.M.; Lima, K.; Cota, B.; Moretzsohn, L.D.; Ribeiro, L.T.; Breyer, H.P.; Maguilnik, I.; Maia, A.B.; Rezende-Filho, J.; Meira, A.C.; Pinto, H.; Alves, E.; Mascarenhas, R.; Passos, R.; de Souza, J.D.; Trindade, O.R.; Coelho, L.G. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J. Gastroenterol., 2016, 22(33), 7587-7594.
[http://dx.doi.org/10.3748/wjg.v22.i33.7587] [PMID: 27672279]
[58]
Di Caro, S.; Franceschi, F.; Mariani, A.; Thompson, F.; Raimondo, D.; Masci, E.; Testoni, A.; La Rocca, E.; Gasbarrini, A. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig. Liver Dis., 2009, 41(7), 480-485.
[http://dx.doi.org/10.1016/j.dld.2008.09.013] [PMID: 18974025]
[59]
Malfertheiner, P.; Bazzoli, F.; Delchier, J-C.; Celiñski, K.; Giguère, M.; Rivière, M.; Mégraud, F.; Group, P.S. Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet, 2011, 377(9769), 905-913.
[http://dx.doi.org/10.1016/S0140-6736(11)60020-2] [PMID: 21345487]
[60]
Chen, Q.; Zhang, W.; Fu, Q.; Liang, X.; Liu, W.; Xiao, S.; Lu, H. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am. J. Gastroenterol., 2016, 111(12), 1736-1742.
[http://dx.doi.org/10.1038/ajg.2016.443] [PMID: 27670603]
[61]
Shiota, S.; Reddy, R.; Alsarraj, A.; El-Serag, H.B.; Graham, D.Y. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin. Gastroenterol. Hepatol., 2015, 13(9), 1616-1624.
[http://dx.doi.org/10.1016/j.cgh.2015.02.005] [PMID: 25681693]
[62]
Mitui, M.; Patel, A.; Leos, N.K.; Doern, C.D.; Park, J.Y. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. J. Pediatr. Gastroenterol. Nutr., 2014, 59(1), 6-9.
[http://dx.doi.org/10.1097/MPG.0000000000000380] [PMID: 25222804]
[63]
Hwang, T.J.; Kim, N.; Kim, H.B.; Lee, B.H.; Nam, R.H.; Park, J.H.; Lee, M.K.; Park, Y.S.; Lee, D.H.; Jung, H.C.; Song, I.S. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J. Clin. Gastroenterol., 2010, 44(8), 536-543.
[http://dx.doi.org/10.1097/MCG.0b013e3181d04592] [PMID: 20179610]
[64]
Mégraud, F.H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut, 2004, 53(9), 1374-1384.
[http://dx.doi.org/10.1136/gut.2003.022111] [PMID: 15306603]
[65]
Torres, J.; Camorlinga-Ponce, M.; Pérez-Pérez, G.; Madrazo-De la Garza, A.; Dehesa, M.; González-Valencia, G.; Muñoz, O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J. Clin. Microbiol., 2001, 39(7), 2677-2680.
[http://dx.doi.org/10.1128/JCM.39.7.2677-2680.2001] [PMID: 11427594]
[66]
Selgrad, M.; Tammer, I.; Langner, C.; Bornschein, J.; Meißle, J.; Kandulski, A.; Varbanova, M.; Wex, T.; Schlüter, D.; Malfertheiner, P. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J. Gastroenterol., 2014, 20(43), 16245-16251.
[http://dx.doi.org/10.3748/wjg.v20.i43.16245] [PMID: 25473179]
[67]
Zhang, Y-X.; Zhou, L-Y.; Song, Z-Q.; Zhang, J-Z.; He, L-H.; Ding, Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study. World J. Gastroenterol., 2015, 21(9), 2786-2792.
[http://dx.doi.org/10.3748/wjg.v21.i9.2786] [PMID: 25759550]
[68]
Wu, H.; Shi, X.D.; Wang, H.T.; Liu, J.X. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J. Antimicrob. Chemother., 2000, 46(1), 121-123.
[http://dx.doi.org/10.1093/jac/46.1.121] [PMID: 10882700]
[69]
Vianna, J.S.; Ramis, I.B.; Ramos, D.F.; VON Groll, A.; Silva, P.E.; von Groll, A.; Silva, P.E.A.D. Drug resistance in Helicobacter pylori. Arq. Gastroenterol., 2016, 53(4), 215-223.
[http://dx.doi.org/10.1590/S0004-28032016000400002] [PMID: 27706449]
[70]
Tompkins, D.S.; Perkin, J.; Smith, C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter, 1997, 2(4), 185-187.
[http://dx.doi.org/10.1111/j.1523-5378.1997.tb00085.x] [PMID: 9421121]
[71]
Jaka, H.; Rüttgerodt, N.; Bohne, W.; Mueller, A.; Gross, U.; Kasang, C.; Mshana, S.E. Helicobacter pylori mutations conferring resistance to fluoroquinolones and clarithromycin among dyspeptic patients attending a tertiary hospital, Tanzania. Canad. J. Gastroenterol. Hepatol., 2019, 2019, 8481375.
[72]
Contreras, M.; Benejat, L.; Mujica, H.; Peña, J.; García-Amado, M-A.; Michelangeli, F.; Lehours, P. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. J. Med. Microbiol., 2019, 68(9), 1287-1291.
[http://dx.doi.org/10.1099/jmm.0.001051] [PMID: 31364966]
[73]
Khademi, F.; Poursina, F.; Hosseini, E.; Akbari, M.; Safaei, H.G. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran. J. Basic Med. Sci., 2015, 18(1), 2-7.
[PMID: 25810869]
[74]
Marques, B.; Donato, M.M.; Cardoso, O.; Luxo, C.; Martinho, A.; Almeida, N. Study of rdxA and frxA genes mutations in metronidazole-resistant and -susceptible Helicobacter pylori clinical isolates from the central region of Portugal. J. Glob. Antimicrob. Resist., 2019, 17, 300-304.
[http://dx.doi.org/10.1016/j.jgar.2019.01.008] [PMID: 30658199]
[75]
Ansari, S.; Yamaoka, Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter, 2017, 22(4), e12386.
[http://dx.doi.org/10.1111/hel.12386] [PMID: 28402047]
[76]
Abadi, A.T.B.; Ierardi, E. Vonoprazan and Helicobacter pylori treatment: A lesson from Japan. Front. Pharmacol., 2019, 10, 316.
[http://dx.doi.org/10.3389/fphar.2019.00316] [PMID: 31024299]
[77]
Labenz, J.; Stolte, M.; Blum, A.L.; Jorias, I.; Leverkus, F.; Sollböhmer, M.; Bertrams, J.; Börsch, G. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: A study in peptic ulcer patients with omeprazole and amoxicillin. Gut, 1995, 37(1), 39-43.
[http://dx.doi.org/10.1136/gut.37.1.39] [PMID: 7672677]
[78]
Verdú, E.F.; Armstrong, D.; Idström, J-P.; Labenz, J.; Stolte, M.; Börsch, G.; Blum, A.L. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori-associated gastritis. Scand. J. Gastroenterol., 1996, 31(12), 1151-1156.
[http://dx.doi.org/10.3109/00365529609036903] [PMID: 8976005]
[79]
Furuta, T.; Shirai, N.; Xiao, F.; Ohashi, K.; Ishizaki, T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther., 2001, 70(5), 484-492.
[http://dx.doi.org/10.1067/mcp.2001.119721] [PMID: 11719736]
[80]
Zhao, F.; Wang, J.; Yang, Y.; Wang, X.; Shi, R.; Xu, Z.; Huang, Z.; Zhang, G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter, 2008, 13(6), 532-541.
[http://dx.doi.org/10.1111/j.1523-5378.2008.00643.x] [PMID: 19166419]
[81]
Furuta, T.; Shirai, N.; Sugimoto, M.; Ohashi, K.; Ishizaki, T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 2004, 5(2), 181-202.
[http://dx.doi.org/10.1517/phgs.5.2.181.27483] [PMID: 15016609]
[82]
Boedicker, J.Q.; Li, L.; Kline, T.R.; Ismagilov, R.F. Detecting bacteria and determining their susceptibility to antibiotics by stochastic confinement in nanoliter droplets using plug-based microfluidics. Lab Chip, 2008, 8(8), 1265-1272.
[http://dx.doi.org/10.1039/b804911d] [PMID: 18651067]
[83]
Debongnie, J.C.; Pauwels, S.; Raat, A.; de Meeus, Y.; Haot, J.; Mainguet, P. Quantification of Helicobacter pylori infection in gastritis and ulcer disease using a simple and rapid carbon-14-urea breath test. J. Nucl. Med., 1991, 32(6), 1192-1198.
[PMID: 2045933]
[84]
Yakoob, J.; Jafri, W.; Abbas, Z.; Abid, S.; Naz, S.; Khan, R.; Khalid, A. Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area. Epidemiol. Infect., 2011, 139(4), 581-590.
[http://dx.doi.org/10.1017/S0950268810001226] [PMID: 20525411]
[85]
Moshkowitz, M.; Konikoff, F.M.; Peled, Y.; Santo, M.; Hallak, A.; Bujanover, Y.; Tiomny, E.; Gilat, T. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut, 1995, 36(6), 845-847.
[http://dx.doi.org/10.1136/gut.36.6.845] [PMID: 7615271]
[86]
Sheu, B-S.; Yang, H-B.; Su, I-J.; Shiesh, S-C.; Chi, C-H.; Lin, X-Z. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest. Endosc., 1996, 44(6), 683-688.
[http://dx.doi.org/10.1016/S0016-5107(96)70052-4] [PMID: 8979058]
[87]
Onal, I.K.; Gokcan, H.; Benzer, E.; Bilir, G.; Oztas, E. What is the impact of Helicobacter pylori density on the success of eradication therapy: A clinico-histopathological study. Clin. Res. Hepatol. Gastroenterol., 2013, 37(6), 642-646.
[http://dx.doi.org/10.1016/j.clinre.2013.05.005] [PMID: 23796974]
[88]
Yamaoka, Y.; Kodama, T.; Kita, M.; Imanishi, J.; Kashima, K.; Graham, D.Y. Relation between clinical presentation, Helicobacter pylori density, interleukin 1β and 8 production, and cagA status. Gut, 1999, 45(6), 804-811.
[http://dx.doi.org/10.1136/gut.45.6.804] [PMID: 10562576]
[89]
Perri, F.; Festa, V.; Clemente, R.; Andriulli, A. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest. Endosc., 1997, 46(3), 287.
[http://dx.doi.org/10.1016/S0016-5107(97)70107-X] [PMID: 9378226]
[90]
Sarem, M.; Corti, R. Role of Helicobacter pylori coccoid forms in infection and recrudescence. Gastroenterol. Hepatol., 2016, 39(1), 28-35.
[http://dx.doi.org/10.1016/j.gastrohep.2015.04.009] [PMID: 26089229]
[91]
Cellini, L.; Allocati, N.; Angelucci, D.; Iezzi, T.; Di Campli, E.; Marzio, L.; Dainelli, B. Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol. Immunol., 1994, 38(11), 843-850.
[http://dx.doi.org/10.1111/j.1348-0421.1994.tb02136.x] [PMID: 7898382]
[92]
Aksit Bıcak, D.; Akyuz, S.; Kıratlı, B.; Usta, M.; Urganci, N.; Alev, B.; Yarat, A.; Sahin, F. The investigation of Helicobacter pylori in the dental biofilm and saliva samples of children with dyspeptic complaints. BMC Oral Health, 2017, 17(1), 67.
[http://dx.doi.org/10.1186/s12903-017-0361-x] [PMID: 28327128]
[93]
Zhao, Y.; Gao, X.; Guo, J.; Yu, D.; Xiao, Y.; Wang, H.; Li, Y. Helicobacter pylori infection alters gastric and tongue coating microbial communities. Helicobacter, 2019, 24(2), e12567.
[http://dx.doi.org/10.1111/hel.12567] [PMID: 30734438]
[94]
Valdez-Gonzalez, J.; Mares-Moreno, P.; Kowolik, M.; Vargas-Villlarreal, J.; Gonzalez-Salazar, F.; De la Garza-Ramos, M. Detection of Helicobacter pylori in dental plaque of Mexican children by real-time PCR. Health, 2014, 6(4), 231-235.
[http://dx.doi.org/10.4236/health.2014.64034]
[95]
Bagirova, M.; Allahverdiyev, A.M.; Abamor, E.S.; Aliyeva, H.; Unal, G.; Tanalp, T.D. An overview of challenges to eradication of Helicobacter pylori infection and future prospects. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(9), 2199-2219.
[PMID: 28537662]
[96]
Oshowo, A.; Tunio, M.; Gillam, D.; Botha, A.J.; Holton, J.; Boulos, P.; Hobsley, M. Oral colonization is unlikely to play an important role in Helicobacter pylori infection. Br. J. Surg., 1998, 85(6), 850-852.
[http://dx.doi.org/10.1046/j.1365-2168.1998.00724.x] [PMID: 9667722]
[97]
Anand, P.S.; Kamath, K.P.; Anil, S. Role of dental plaque, saliva and periodontal disease in Helicobacter pylori infection. World J. Gastroenterol., 2014, 20(19), 5639-5653.
[http://dx.doi.org/10.3748/wjg.v20.i19.5639] [PMID: 24914323]
[98]
Young, K.A.; Allaker, R.P.; Hardie, J.M. Morphological analysis of Helicobacter pylori from gastric biopsies and dental plaque by scanning electron microscopy. Oral Microbiol. Immunol., 2001, 16(3), 178-181.
[http://dx.doi.org/10.1034/j.1399-302x.2001.016003178.x] [PMID: 11358540]
[99]
Semino-Mora, C.; Doi, S.Q.; Marty, A.; Simko, V.; Carlstedt, I.; Dubois, A. Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J. Infect. Dis., 2003, 187(8), 1165-1177.
[http://dx.doi.org/10.1086/368133] [PMID: 12695995]
[100]
Takenaka, R.; Yokota, K.; Ayada, K.; Mizuno, M.; Zhao, Y.; Fujinami, Y.; Lin, S-N.; Toyokawa, T.; Okada, H.; Shiratori, Y.; Oguma, K. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology, 2004, 150(Pt 12), 3913-3922.
[http://dx.doi.org/10.1099/mic.0.27527-0] [PMID: 15583145]
[101]
Huang, Y.; Wang, Q.L.; Cheng, D.D.; Xu, W.T.; Lu, N.H. Adhesion and invasion of gastric mucosa epithelial cells by Helicobacter pylori. Front. Cell. Infect. Microbiol., 2016, 6, 159.
[http://dx.doi.org/10.3389/fcimb.2016.00159] [PMID: 27921009]
[102]
Björkholm, B.; Zhukhovitsky, V.; Löfman, C.; Hultén, K.; Enroth, H.; Block, M.; Rigo, R.; Falk, P.; Engstrand, L. Helicobacter pylori entry into human gastric epithelial cells: A potential determinant of virulence, persistence, and treatment failures. Helicobacter, 2000, 5(3), 148-154.
[http://dx.doi.org/10.1046/j.1523-5378.2000.00023.x] [PMID: 10971679]
[103]
Wyle, F.A.; Tarnawski, A.; Schulman, D.; Dabros, W. Evidence for gastric mucosal cell invasion by C. pylori: An ultrastructural study. J. Clin. Gastroenterol., 1990, 12(Suppl. 1), S92-S98.
[http://dx.doi.org/10.1097/00004836-199001001-00016] [PMID: 2212556]
[104]
Matysiak-Budnik, T.; Heyman, M.; Candalh, C.; Lethuaire, D.; Mégraud, F. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: Effect of Helicobacter pylori. J. Antimicrob. Chemother., 2002, 50(6), 865-872.
[http://dx.doi.org/10.1093/jac/dkf219] [PMID: 12461005]
[105]
Kamada, N.; Sakamoto, K.; Seo, S-U.; Zeng, M.Y.; Kim, Y-G.; Cascalho, M.; Vallance, B.A.; Puente, J.L.; Núñez, G. Humoral immunity in the gut selectively targets phenotypically virulent attaching-and-effacing bacteria for intraluminal elimination. Cell Host Microbe, 2015, 17(5), 617-627.
[http://dx.doi.org/10.1016/j.chom.2015.04.001] [PMID: 25936799]
[106]
Larussa, T.; Leone, I.; Suraci, E.; Imeneo, M.; Luzza, F. Helicobacter pylori and T helper cells: Mechanisms of immune escape and tolerance. J. Immunol. Res., 2015, 2015, 981328.
[107]
Del Giudice, G.; Michetti, P. Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter, 2004, 9(Suppl. 1), 23-28.
[http://dx.doi.org/10.1111/j.1083-4389.2004.00245.x] [PMID: 15347302]
[108]
Djekic, A.; Müller, A. The immunomodulator VacA promotes immune tolerance and persistent Helicobacter pylori infection through its activities on T-cells and antigen-presenting cells. Toxins (Basel), 2016, 8(6), 187.
[http://dx.doi.org/10.3390/toxins8060187] [PMID: 27322319]
[109]
Ko, S.H.; Jeon, J.I.; Kim, Y-J.; Yoon, H.J.; Kim, H.; Kim, N.; Kim, J.S.; Kim, J.M. Helicobacter pylori outer membrane vesicle proteins induce human eosinophil degranulation via a β2 Integrin CD11/CD18-and ICAM-1-dependent mechanism. Mediators of Inflammation., 2015.
[110]
van der Ende, A.; van der Hulst, R.W.; Dankert, J.; Tytgat, G.N. Reinfection versus recrudescence in Helicobacter pylori infection. Aliment. Pharmacol. Ther., 1997, 11(Suppl. 1), 55-61.
[http://dx.doi.org/10.1046/j.1365-2036.11.s1.10.x] [PMID: 9146791]
[111]
Hildebrand, P.; Bardhan, P.; Rossi, L.; Parvin, S.; Rahman, A.; Arefin, M.S.; Hasan, M.; Ahmad, M.M.; Glatz-Krieger, K.; Terracciano, L.; Bauerfeind, P.; Beglinger, C.; Gyr, N.; Khan, A.K. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology, 2001, 121(4), 792-798.
[http://dx.doi.org/10.1053/gast.2001.28018] [PMID: 11606492]
[112]
Okimoto, T.; Murakami, K.; Sato, R.; Miyajima, H.; Nasu, M.; Kagawa, J.; Kodama, M.; Fujioka, T. Is the recurrence of Helicobacter pylori infection after eradication therapy resultant from recrudescence or reinfection, in Japan. Helicobacter, 2003, 8(3), 186-191.
[http://dx.doi.org/10.1046/j.1523-5378.2003.00143.x] [PMID: 12752730]
[113]
Xia, H.X.; Windle, H.J.; Marshall, D.G.; Smyth, C.J.; Keane, C.T.; O’Morain, C.A. Recrudescence of Helicobacter pylori after apparently successful eradication: Novel application of randomly amplified polymorphic DNA fingerprinting. Gut, 1995, 37(1), 30-34.
[http://dx.doi.org/10.1136/gut.37.1.30] [PMID: 7672675]
[114]
Jonaitis, L.; Kiudelis, G.; Slepavicius, P.; Kupcinskas, L. High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients. World J. Gastrointest. Pathophysiol., 2016, 7(1), 181-185.
[http://dx.doi.org/10.4291/wjgp.v7.i1.181] [PMID: 26909241]
[115]
Benajah, D.A.; Lahbabi, M.; Alaoui, S.; El Rhazi, K.; El Abkari, M.; Nejjari, C.; Amarti, A.; Bennani, B.; Mahmoud, M.; Ibrahimi, S.A. Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). Clin. Res. Hepatol. Gastroenterol., 2013, 37(5), 519-526.
[http://dx.doi.org/10.1016/j.clinre.2013.02.003] [PMID: 23567104]
[116]
Vilaichone, R.K.; Wongcha Um, A.; Chotivitayatarakorn, P. Low re-infection rate of Helicobacter pylori after successful eradication in Thailand: A 2 years study. Asian Pacific journal of cancer prevention. Asian Pac. J. Cancer Prev., 2017, 18(3), 695-697.
[PMID: 28440977]
[117]
Kim, M.S.; Kim, N.; Kim, S.E.; Jo, H.J.; Shin, C.M.; Lee, S.H.; Park, Y.S.; Hwang, J.H.; Kim, J.W.; Jeong, S.H.; Lee, D.H.; Kim, J.M.; Jung, H.C. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter, 2013, 18(2), 135-142.
[http://dx.doi.org/10.1111/hel.12018] [PMID: 23066652]
[118]
ZHANG. Y.Y.; XIA, H.X.; ZHUANG, Z.H.; Zhong, J., ‘true’re‐infection of Helicobacter pylori after successful eradication-worldwide annual rates, risk factors and clinical implications. Aliment. Pharmacol. Ther., 2009, 29(2), 145-160.
[http://dx.doi.org/10.1111/j.1365-2036.2008.03873.x] [PMID: 18945250]
[119]
Kanbay, M.; Gür, G.; Arslan, H.; Yilmaz, U.; Boyacioĝlu, S. The relationship of ABO blood group, age, gender, smoking, and Helicobacter pylori infection. Dig. Dis. Sci., 2005, 50(7), 1214-1217.
[http://dx.doi.org/10.1007/s10620-005-2762-y] [PMID: 16047462]
[120]
Suzuki, T.; Matsuo, K.; Ito, H.; Sawaki, A.; Hirose, K.; Wakai, K.; Sato, S.; Nakamura, T.; Yamao, K.; Ueda, R.; Tajima, K. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med., 2006, 119(3), 217-224.
[http://dx.doi.org/10.1016/j.amjmed.2005.10.003] [PMID: 16490464]
[121]
Li, G.; Wulan, H.; Song, Z.; Paik, P.A.; Tsao, M.L.; Goodman, G.M.; MacEachern, P.T.; Downey, R.S.; Jankowska, A.J.; Rabinowitz, Y.M.; Learch, T.B.; Song, D.Z.; Yuan, J.J.; Zheng, S.; Zheng, Z.; Regulatory, B. Regulatory B cell function is suppressed by smoking and obesity in H. pylori-infected subjects and is correlated with elevated risk of gastric cancer. PLoS One, 2015, 10(7), e0134591.
[http://dx.doi.org/10.1371/journal.pone.0134591] [PMID: 26226399]
[122]
Murakami, T.T.; Scranton, R.A.; Brown, H.E.; Harris, R.B.; Chen, Z.; Musuku, S.; Oren, E. Management of Helicobacter pylori in the United States: Results from a national survey of gastroenterology physicians. Prev. Med., 2017, 100, 216-222.
[http://dx.doi.org/10.1016/j.ypmed.2017.04.021] [PMID: 28457713]
[123]
Chuah, Y.Y.; Wu, D.C.; Chuah, S.K.; Yang, J.C.; Lee, T.H.; Yeh, H.Z.; Chen, C.L.; Liu, Y.H.; Hsu, P.I. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter pylori eradication (REAP-HP Survey). Helicobacter, 2017, 22(3), e12380.
[http://dx.doi.org/10.1111/hel.12380] [PMID: 28244264]
[124]
Yonezawa, H.; Osaki, T.; Hanawa, T.; Kurata, S.; Ochiai, K.; Kamiya, S. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. PLoS One, 2013, 8(9), e73301.
[http://dx.doi.org/10.1371/journal.pone.0073301] [PMID: 24039906]
[125]
Sharahi, J.Y.; Azimi, T.; Shariati, A.; Safari, H.; Tehrani, M.K.; Hashemi, A. Advanced strategies for combating bacterial biofilms. J. Cell. Physiol., 2019, 234(9), 14689-14708.
[http://dx.doi.org/10.1002/jcp.28225] [PMID: 30693517]
[126]
Yonezawa, H.; Osaki, T.; Kamiya, S. Biofilm formation by Helicobacter pylori and its involvement for antibiotic resistance. BioMed research international, 2015, 2015, 914791.
[127]
Nazari, P.; Dowlatabadi-Bazaz, R.; Mofid, M.R.; Pourmand, M.R.; Daryani, N.E.; Faramarzi, M.A.; Sepehrizadeh, Z.; Shahverdi, A.R. The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori. Appl. Biochem. Biotechnol., 2014, 172(2), 570-579.
[http://dx.doi.org/10.1007/s12010-013-0571-x] [PMID: 24104691]
[128]
Cammarota, G.; Sanguinetti, M.; Gallo, A.; Posteraro, B. Review article: Biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment. Pharmacol. Ther., 2012, 36(3), 222-230.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05165.x] [PMID: 22650647]
[129]
Flemming, H-C.; Wingender, J.; Szewzyk, U.; Steinberg, P.; Rice, S.A.; Kjelleberg, S. Biofilms: An emergent form of bacterial life. Nat. Rev. Microbiol., 2016, 14(9), 563-575.
[http://dx.doi.org/10.1038/nrmicro.2016.94] [PMID: 27510863]
[130]
Kuipers, E.J. Helicobacter pylori and the risk and management of associated diseases: Gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment. Pharmacol. Ther., 1997, 11(S1)(Suppl. 1), 71-88.
[http://dx.doi.org/10.1046/j.1365-2036.11.s1.5.x] [PMID: 9146793]
[131]
Forman, D.; Graham, D.Y. Review article: Impact of Helicobacter pylori on society-role for a strategy of ‘search and eradicate’. Aliment. Pharmacol. Ther., 2004, 19(Suppl. 1), 17-21.
[http://dx.doi.org/10.1111/j.0953-0673.2004.01831.x] [PMID: 14725574]
[132]
Sánchez, B.; Delgado, S.; Blanco-Míguez, A.; Lourenço, A.; Gueimonde, M.; Margolles, A. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res., 2017, 61(1), 1600240.
[http://dx.doi.org/10.1002/mnfr.201600240] [PMID: 27500859]
[133]
Qureshi, N.; Li, P.; Gu, Q. Probiotic therapy in Helicobacter pylori infection: A potential strategy against a serious pathogen? Appl. Microbiol. Biotechnol., 2019, 103(4), 1573-1588.
[http://dx.doi.org/10.1007/s00253-018-09580-3] [PMID: 30610283]
[134]
García, A.; Navarro, K.; Sanhueza, E.; Pineda, S.; Pastene, E.; Quezada, M.; Henríquez, K.; Karlyshev, A.; Villena, J.; González, C. Characterization of Lactobacillus fermentum UCO-979C, a probiotic strain with a potent anti-Helicobacter pylori activity. Electron. J. Biotechnol., 2017, 25, 75-83.
[http://dx.doi.org/10.1016/j.ejbt.2016.11.008]
[135]
Goderska, K.; Agudo Pena, S.; Alarcon, T. Helicobacter pylori treatment: Antibiotics or probiotics. Appl. Microbiol. Biotechnol., 2018, 102(1), 1-7.
[http://dx.doi.org/10.1007/s00253-017-8535-7] [PMID: 29075827]
[136]
Losurdo, G.; Cubisino, R.; Barone, M.; Principi, M.; Leandro, G.; Ierardi, E.; Di Leo, A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J. Gastroenterol., 2018, 24(1), 139-149.
[http://dx.doi.org/10.3748/wjg.v24.i1.139] [PMID: 29358890]
[137]
Kafshdooz, T.; Akbarzadeh, A.; Seghinsara, M.A.; Pourhassan, M.; Nasrabadi, H.T.; Milani, M. Role of probiotics in managing of Helicobacter pylori infection: A review. Drug Res. (Stuttg.), 2017, 67(2), 88-93.
[PMID: 27824431]
[138]
Narayana, J.L.; Huang, H-N.; Wu, C-J.; Chen, J-Y. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model. Biomaterials, 2015, 61, 41-51.
[http://dx.doi.org/10.1016/j.biomaterials.2015.05.014] [PMID: 25996410]
[139]
Deslouches, B.; Di, Y.P. Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications. Oncotarget, 2017, 8(28), 46635-46651.
[http://dx.doi.org/10.18632/oncotarget.16743] [PMID: 28422728]
[140]
Lee, J-K.; Park, S-C.; Hahm, K-S.; Park, Y. A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice. Biomaterials, 2014, 35(3), 1025-1039.
[http://dx.doi.org/10.1016/j.biomaterials.2013.10.035] [PMID: 24176194]
[141]
Zhang, X.; Jiang, A.; Qi, B.; Yu, H.; Xiong, Y.; Zhou, G.; Qin, M.; Dou, J.; Wang, J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl. Microbiol. Biotechnol., 2018, 102(11), 4817-4827.
[http://dx.doi.org/10.1007/s00253-018-8982-9] [PMID: 29675800]
[142]
Iwahori, A.; Hirota, Y.; Sampe, R.; Miyano, S.; Takahashi, N.; Sasatsu, M.; Kondo, I.; Numao, N. On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Biol. Pharm. Bull., 1997, 20(7), 805-808.
[http://dx.doi.org/10.1248/bpb.20.805] [PMID: 9255424]
[143]
Narayana, J.L.; Huang, H-N.; Wu, C-J.; Chen, J-Y. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: In vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget, 2015, 6(15), 12936-12954.
[http://dx.doi.org/10.18632/oncotarget.4101] [PMID: 26002554]
[144]
Zhang, L.; Yu, J.; Wong, C.C.; Ling, T.K.; Li, Z.J.; Chan, K.M.; Ren, S.X.; Shen, J.; Chan, R.L.; Lee, C.C.; Li, M.S.; Cheng, A.S.; To, K.F.; Gallo, R.L.; Sung, J.J.; Wu, W.K.; Cho, C.H. Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice. Gene Ther., 2013, 20(7), 751-760.
[http://dx.doi.org/10.1038/gt.2012.92] [PMID: 23254369]
[145]
Guzman, J.; Téné, N.; Touchard, A.; Castillo, D.; Belkhelfa, H.; Haddioui-Hbabi, L.; Treilhou, M.; Sauvain, M. Anti-Helicobacter pylori properties of the ant-venom peptide bicarinalin. Toxins (Basel), 2017, 10(1), 21.
[http://dx.doi.org/10.3390/toxins10010021] [PMID: 29286296]
[146]
Chen, L.; Li, Y.; Li, J.; Xu, X.; Lai, R.; Zou, Q. An antimicrobial peptide with antimicrobial activity against Helicobacter pylori. Peptides, 2007, 28(8), 1527-1531.
[http://dx.doi.org/10.1016/j.peptides.2007.07.007] [PMID: 17698252]
[147]
Zhang, X.; Jiang, A.; Wang, G.; Yu, H.; Qi, B.; Xiong, Y.; Zhou, G.; Qin, M.; Dou, J.; Wang, J. Fusion expression of the PGLa-AM1 with native structure and evaluation of its anti-Helicobacter pylori activity. Appl. Microbiol. Biotechnol., 2017, 101(14), 5667-5675.
[http://dx.doi.org/10.1007/s00253-017-8302-9] [PMID: 28488117]
[148]
Kim, T-S.; Hur, J-W.; Yu, M-A.; Cheigh, C-I.; Kim, K-N.; Hwang, J-K.; Pyun, Y-R. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J. Food Prot., 2003, 66(1), 3-12.
[http://dx.doi.org/10.4315/0362-028X-66.1.3] [PMID: 12540174]
[149]
Huang, H-N.; Rajanbabu, V.; Pan, C-Y.; Chan, Y-L.; Wu, C-J.; Chen, J-Y. Use of the antimicrobial peptide Epinecidin-1 to protect against MRSA infection in mice with skin injuries. Biomaterials, 2013, 34(38), 10319-10327.
[http://dx.doi.org/10.1016/j.biomaterials.2013.09.037] [PMID: 24075409]
[150]
Bechinger, B.; Gorr, S-U. Antimicrobial peptides: Mechanisms of action and resistance. J. Dent. Res., 2017, 96(3), 254-260.
[http://dx.doi.org/10.1177/0022034516679973] [PMID: 27872334]
[151]
Neshani, A.; Zare, H.; Akbari Eidgahi, M.R.; Hooshyar, C.A.; Movaqar, A.; Ghazvini, K. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter, 2019, 24(1), e12555.
[http://dx.doi.org/10.1111/hel.12555] [PMID: 30440101]
[152]
Yasbolaghi Sharahi, J.; Aliakbar Ahovan, Z.; Taghizadeh Maleki, D.; Riahi Rad, Z.; Riahi Rad, Z.; Goudarzi, M.; Shariati, A.; Bostanghadiri, N.; Abbasi, E.; Hashemi, A. In vitro antibacterial activity of curcumin-meropenem combination against Extensively Drug-Resistant (XDR) bacteria isolated from burn wound infections. Avicenna J. Phytomed., 2020, 10(1), 3-10.
[PMID: 31921603]
[153]
Shariati, A.; Asadian, E.; Fallah, F.; Azimi, T.; Hashemi, A.; Yasbolaghi, S.J.; Moghadam, T.M. Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from burn wound infection in Tehran, Iran. Infect. Drug Resist., 2019, 12, 2223-2235.
[http://dx.doi.org/10.2147/IDR.S213200] [PMID: 31440064]
[154]
Slavin, Y.N.; Asnis, J.; Häfeli, U.O.; Bach, H. Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. J. Nanobiotechnology, 2017, 15(1), 65.
[http://dx.doi.org/10.1186/s12951-017-0308-z] [PMID: 28974225]
[155]
Amin, M.; Anwar, F.; Naz, F.; Mehmood, T.; Saari, N. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. Molecules, 2013, 18(2), 2135-2149.
[http://dx.doi.org/10.3390/molecules18022135] [PMID: 23434867]
[156]
Lima, Z.P.; Bonamin, F.; Calvo, T.R.; Vilegas, W.; Santos, L.C.; Rozza, A.L.; Pellizzon, C.H.; Rocha, L.R.; Hiruma-Lima, C.A. Effects of the ethyl acetate fraction of Alchornea triplinervia on healing gastric ulcer in rats. Pharmaceuticals (Basel), 2011, 4(11), 1423-1433.
[http://dx.doi.org/10.3390/ph4111423] [PMID: 26791640]
[157]
Mafioleti, L.; da Silva, Junior, I.F.; Colodel, E.M.; Flach, A.; Martins, D.T. Evaluation of the toxicity and antimicrobial activity of hydroethanolic extract of Arrabidaea chica (Humb. & Bonpl.). B. Verl. J. Ethnopharmacol., 2013, 150(2), 576-582.
[http://dx.doi.org/10.1016/j.jep.2013.09.008] [PMID: 24070833]
[158]
Okeleye, B.I.; Bessong, P.O.; Ndip, R.N. Preliminary phytochemical screening and in vitro anti-Helicobacter pylori activity of extracts of the stem bark of Bridelia micrantha (Hochst., Baill., Euphorbiaceae). Molecules, 2011, 16(8), 6193-6205.
[http://dx.doi.org/10.3390/molecules16086193] [PMID: 21788928]
[159]
Souza, Mdo.; C., Beserra; Beserra, A.M.S.; Martins, D.C.; Real, V.V.; Santos, R.A.; Rao, V.S.; Silva, R.M.; Martins, D.T. In vitro and in vivo anti-Helicobacter pylori activity of Calophyllum brasiliense Camb. J. Ethnopharmacol., 2009, 123(3), 452-458.
[http://dx.doi.org/10.1016/j.jep.2009.03.030] [PMID: 19501278]
[160]
Diker, K.; Hascelik, G. The bactericidal activity of tea against Helicobacter pylori. Lett. Appl. Microbiol., 1994, 19(5), 299-300.
[http://dx.doi.org/10.1111/j.1472-765X.1994.tb00459.x]
[161]
Putri, D.U.; Rintiswati, N.; Soesatyo, M.H.; Haryana, S.M. Immune modulation properties of herbal plant leaves: Phyllanthus niruri aqueous extract on immune cells of tuberculosis patient - in vitro study. Nat. Prod. Res., 2018, 32(4), 463-467.
[http://dx.doi.org/10.1080/14786419.2017.1311888] [PMID: 28391709]
[162]
Karimi, E.; Mehrabanjoubani, P.; Homayouni-Tabrizi, M.; Abdolzadeh, A.; Soltani, M. Phytochemical evaluation, antioxidant properties and antibacterial activity of Iranian medicinal herb Galanthus transcaucasicus Fomin. J. Food Meas. Charact., 2018, 12(1), 433-440.
[http://dx.doi.org/10.1007/s11694-017-9656-5]
[163]
Wang, Y-C. Medicinal plant activity on Helicobacter pylori related diseases. World J. Gastroenterol., 2014, 20(30), 10368-10382.
[http://dx.doi.org/10.3748/wjg.v20.i30.10368] [PMID: 25132753]
[164]
Cai, J.; Huang, H.; Song, W.; Hu, H.; Chen, J.; Zhang, L.; Li, P.; Wu, R.; Wu, C. Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int. J. Pharm., 2015, 495(2), 728-737.
[http://dx.doi.org/10.1016/j.ijpharm.2015.09.055] [PMID: 26417849]
[165]
Pan-In, P.; Banlunara, W.; Chaichanawongsaroj, N.; Wanichwecharungruang, S. Ethyl cellulose nanoparticles: Clarithomycin encapsulation and eradication of H. pylori. Carbohydr. Polym., 2014, 109, 22-27.
[http://dx.doi.org/10.1016/j.carbpol.2014.03.025] [PMID: 24815396]
[166]
Lin, Y.H.; Lin, J.H.; Chou, S.C.; Chang, S.J.; Chung, C.C.; Chen, Y.S.; Chang, C.H. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: In vitro and in vivo study. Nanomedicine, (Lond.), 2015, 10(1), 57-71.
[http://dx.doi.org/10.2217/nnm.14.76] [PMID: 25177920]
[167]
Safarov, T.; Kiran, B.; Bagirova, M.; Allahverdiyev, A.M.; Abamor, E.S. An overview of nanotechnology-based treatment approaches against Helicobacter pylori. Expert Rev. Anti Infect. Ther., 2019, 17(10), 829-840.
[http://dx.doi.org/10.1080/14787210.2019.1677464]
[168]
Kleanthous, H.; Lee, C.K.; Monath, T.P. Vaccine development against infection with Helicobacter pylori. Br. Med. Bull., 1998, 54(1), 229-241.
[http://dx.doi.org/10.1093/oxfordjournals.bmb.a011673] [PMID: 9604446]
[169]
Michetti, P.; Corthésy-Theulaz, I.; Davin, C.; Haas, R.; Vaney, A-C.; Heitz, M.; Bille, J.; Kraehenbuhl, J-P.; Saraga, E.; Blum, A.L. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology, 1994, 107(4), 1002-1011.
[http://dx.doi.org/10.1016/0016-5085(94)90224-0] [PMID: 7926454]
[170]
Del Giudice, G.; Covacci, A.; Telford, J.L.; Montecucco, C.; Rappuoli, R. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol., 2001, 19(1), 523-563.
[http://dx.doi.org/10.1146/annurev.immunol.19.1.523] [PMID: 11244046]
[171]
Wu, C.; Shi, Y.; Guo, H.; Zou, W.Y.; Guo, G.; Xie, Q.H.; Mao, X.H.; Tong, W.D.; Zou, Q.M. Protection against Helicobacter pylori infection in Mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter, 2008, 13(3), 191-199.
[http://dx.doi.org/10.1111/j.1523-5378.2008.00609.x] [PMID: 18466394]
[172]
Gong, Y.; Tao, L.; Wang, F.; Liu, W.; Jing, L.; Liu, D.; Hu, S.; Xie, Y.; Zhou, N. Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine. Mol. Med. Rep., 2015, 12(3), 4123-4132.
[http://dx.doi.org/10.3892/mmr.2015.3950] [PMID: 26095723]
[173]
Radcliff, F.J.; Hazell, S.L.; Kolesnikow, T.; Doidge, C.; Lee, A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun., 1997, 65(11), 4668-4674.
[http://dx.doi.org/10.1128/IAI.65.11.4668-4674.1997] [PMID: 9353048]
[174]
Michetti, P.; Kreiss, C.; Kotloff, K.L.; Porta, N.; Blanco, J.L.; Bachmann, D.; Herranz, M.; Saldinger, P.F.; Corthésy-Theulaz, I.; Losonsky, G.; Nichols, R.; Simon, J.; Stolte, M.; Ackerman, S.; Monath, T.P.; Blum, A.L. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology, 1999, 116(4), 804-812.
[http://dx.doi.org/10.1016/S0016-5085(99)70063-6] [PMID: 10092302]
[175]
Selgrad, M.; Malfertheiner, P. New strategies for Helicobacter pylori eradication. Curr. Opin. Pharmacol., 2008, 8(5), 593-597.
[http://dx.doi.org/10.1016/j.coph.2008.04.010] [PMID: 18555746]
[176]
Munoz, N.; Sanchez-Delgado, J.; Baylina, M.; Lopez-Gongora, S.; Calvet, X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterología y Hepatología; English Edition, 2018.
[177]
Nezafat, N.; Eslami, M.; Negahdaripour, M.; Rahbar, M.R.; Ghasemi, Y. Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. Mol. Biosyst., 2017, 13(4), 699-713.
[http://dx.doi.org/10.1039/C6MB00772D] [PMID: 28194462]
[178]
Zeng, M.; Mao, X-H.; Li, J-X.; Tong, W-D.; Wang, B.; Zhang, Y-J.; Guo, G.; Zhao, Z-J.; Li, L.; Wu, D-L.; Lu, D.S.; Tan, Z.M.; Liang, H.Y.; Wu, C.; Li, D.H.; Luo, P.; Zeng, H.; Zhang, W.J.; Zhang, J.Y.; Guo, B.T.; Zhu, F.C.; Zou, Q.M. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2015, 386(10002), 1457-1464.
[http://dx.doi.org/10.1016/S0140-6736(15)60310-5] [PMID: 26142048]
[179]
O’Riordan, A.A.; Morales, V.A.; Mulligan, L.; Faheem, N.; Windle, H.J.; Kelleher, D.P. Alkyl hydroperoxide reductase: A candidate Helicobacter pylori vaccine. Vaccine, 2012, 30(26), 3876-3884.
[http://dx.doi.org/10.1016/j.vaccine.2012.04.002] [PMID: 22512976]
[180]
Sheu, B.S.; Wu, J.J.; Lo, C.Y.; Wu, H.W.; Chen, J.H.; Lin, Y.S.; Lin, M.D. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 2002, 16(9), 1669-1675.
[http://dx.doi.org/10.1046/j.1365-2036.2002.01335.x] [PMID: 12197847]
[181]
Zojaji, H.; Ghobakhlou, M.; Rajabalinia, H.; Ataei, E.; Jahani Sherafat, S.; Moghimi-Dehkordi, B.; Bahreiny, R. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H. pylori: A randomized controlled trial. Gastroenterol. Hepatol. Bed Bench, 2013, 6(Suppl. 1), S99-S104.
[PMID: 24834296]
[182]
Nostro, A.; Cellini, L.; Di Bartolomeo, S.; Di Campli, E.; Grande, R.; Cannatelli, M.A.; Marzio, L.; Alonzo, V. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother. Res., 2005, 19(3), 198-202.
[http://dx.doi.org/10.1002/ptr.1640] [PMID: 15934015]
[183]
Kouitcheu, M.L.B.; Eyoum, B.B.; Tchouangueu, T.F.; Nguepi, E.; Leundji, H. Treatment of Helicobacter pylori infected mice with Bryophyllum pinnatum, a medicinal plant with antioxidant and antimicrobial properties, reduces bacterial load. Pharm. Biol., 2017, 55(1), 603-610.
[http://dx.doi.org/10.1080/13880209.2016.1266668] [PMID: 27937097]
[184]
Lee, H-A.; Hong, S.; Yoo, J-H.; Chung, Y.; Kim, O. Anti-Helicobacter pylori activity and inhibition of gastritis by Allium hookeri extract. Lab. Anim. Res., 2018, 34(2), 75-79.
[http://dx.doi.org/10.5625/lar.2018.34.2.75] [PMID: 29937914]
[185]
Sharaf, S.M.; Abbas, H.S.; Ismaeil, T.A. Characterization of spirugenic iron oxide nanoparticles and their antibacterial activity against multidrug-resistant Helicobacter pylori. Egyptian J. Phycol., 2019, 20(2)
[186]
Gopinath, V.; Priyadarshini, S.; MubarakAli, D.; Loke, M.F.; Thajuddin, N.; Alharbi, N.S.; Yadavalli, T.; Alagiri, M.; Vadivelu, J. Anti-Helicobacter pylori, cytotoxicity and catalytic activity of biosynthesized gold nanoparticles: Multifaceted application. Arab. J. Chem., 2019, 33-40.

Rights & Permissions Print Cite
Article Metrics
42
1
© 2024 Bentham Science Publishers | Privacy Policy